SI 613Alternative Names: Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; Non-steroidal anti-inflammatory drug/hyaluronic acid; NSAID/hyaluronic acid; SI-613
Latest Information Update: 03 Feb 2017
At a glance
- Originator Seikagaku Corporation
- Class Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoarthritis